HK Stock Market Move | AIM VACCINE (06660) rose more than 7% in intraday trading, with the declaration of clinical trials for the second-generation rabies vaccine. Updates on the progress of applications for multiple products will be announced soon.

AIM VACCINE (06660) rose more than 7% in midday trading, and as of the time of writing, it was up 5.01% to 8.18 Hong Kong dollars, with a trading volume of 57.42 million Hong Kong dollars. In terms of news, AIM VACCINE announced that the group's developed efficient bivalent human diploid cell rabies vaccine iteration process has recently been submitted for clinical review to the Drug Evaluation Center (CDE) of the China Food and Drug Administration. It is reported that the group has completed the construction of a production workshop for the efficient bivalent human diploid cell rabies vaccine iteration process that meets international standards and has completed the production of samples for the commercial-scale phase III clinical trial, demonstrating the ability to produce this product on a large scale. Furthermore, earlier this month, AIM VACCINE announced that the independently developed 13-valent pneumococcal conjugate vaccine has been submitted for drug registration approval to the National Medical Products Administration. In addition, a mRNA respiratory syncytial virus (RSV) vaccine developed by the group's subsidiary, Zhuhai Lifant Biotechnology Co., Ltd., has recently received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, marking a new stage in the development of this vaccine.